Mesoblast Ltd ADR (MESO)

[SuperSquirrel]

Mesoblast Limited (ASX:MSB) (PINK:MBLTY) wishes to inform the market that the Board of its strategic partner Cephalon Inc. (NASDAQ:CEPH) has rejected the unsolicited proposal from Valeant Pharmaceuticals International Inc (NYSE:VRX) to acquire its issued share capital or certain assets.

Melbourne, April 7, 2011 (ABN Newswire) -

The full Cephalon response can be viewed at: http://www.cephalon.com/media/news-releases.html

Reflecting on the value of its pipeline, the Cephalon Board said it "has created one of the broadest pipelines in the industry, with 10 late-stage product candidates targeted at novel and 'best-in-class' therapeutics. This includes six indications with blockbuster potential which are projected to begin launching in the next three years."


About Mesoblast Limited

Mesoblast Limited (ASX:MSB) (PINK:MBLTY) is a world leader in commercializing biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com

Contact
Julie Meldrum
Corporate Communications Director
T: [phone]
C: [phone]
Email:[e-mail]

Link: http://www.abnnewswire.net/media/en/docs/353086.pdf